Agonists and antagonists acting at P2X7 receptor

Current Topics in Medicinal Chemistry

Volumn 4, Issue 16, 2004, Pages 1707-1717

  Baraldi, Pier Giovanni ^a   Di Virgilio, Francesco ^a   Romagnoli, Romeo ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

Agonist; Antagonist; ATP receptor; Ionotropic receptor; P2X7 purinoreceptor

Indexed keywords

1 [N,O BIS(1, 5 ISOQUINOLINESULFONYL) N TYROSYL] 4, TERTBUTYLOXYCARBONYLPIPERAZINE; 1 [N,O BIS(5 ISOQUINOLINESULFONYL) N METHYLTYROSYL] 4 PHENYLPIPERAZINE; 2 CHLOROADENOSINE TRIPHOSPHATE; 2 METHYLTHIOADENOSINE TRIPHOSPHATE; 2',3' O (4 BENZOYL)BENZOYLADENOSINE TRIPHOSPHATE; 2,3 DIALDEHYDE ADENOSINE TRIPHOSPHATE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 3 NITROBENZYLOXYCARBONYL DERIVATIVE; 4 AMINOTOLUNSULFONATE; 4 NITROTOLUNSULFONATE; 5' (N,N' HEXAMETHYLENE)AMILORIDE; 5' P FLUOROSULPHONYL BENZOYLADENOSINE; [N BENZYLOXYCARBONYL O (4 ISOQUINOLINESULFONYL)TYROSYL]BENZOYLPIPERAZINE; ADAMANTANE DERIVATIVE; ALPHA,BETA METHYLENEADENOSINE TRIPHOSPHATE; BRILLIANT BLUE; CALMIDAZOLIUM; CIBACRON BLUE F3GA; GLUTARIMIDE DERIVATIVE; MRS 2306; MRS 2409; MRS 2447; MRS 2452; MRS 2464; N [1 [4 (5 ISOQUINOLINESULFONYL) ALPHA METHYLBENZYL] 2 (4 PHENYL 1 PIPERAZINYL)ETHYL] 5 ISOQUINOLINESULFONAMIDE; NITROGEN OXIDE; PURINE P2X7 RECEPTOR; PURINE P2X7 RECEPTOR BLOCKING AGENT; PURINERGIC RECEPTOR BLOCKING AGENT; PURINERGIC RECEPTOR STIMULATING AGENT; RECOMBINANT RECEPTOR; SUCCINIMIDE DERIVATIVE; SURAMIN; TYROSINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; CYTOKINE RELEASE; CYTOTOXICITY; DRUG CONFORMATION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TARGETING; HUMAN; IC 50; REVIEW; STRUCTURE ACTIVITY RELATION; SYSTEMATIC REVIEW;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ADENOSINE TRIPHOSPHATE; ANIMALS; HUMANS; RECEPTORS, PURINERGIC P2; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 10644256586     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568026043387223     Document Type: Review

References (59)

1. Di Virgilio, F. The P2Z purinoceptor: an intriguing role in immunity, inflammation and cell death. Immunol. Today 1995, 16, 524-528.
2. North, R. A. Molecular physiology of P2X receptors. Physiol. Rev. 2002, 82, 1013-1067.
3. Di Virgilio, F.; Chiozzi, P.; Ferrari, D.; Falzoni, S.; Sanz, J.M.; Morelli, A.; Torboli, M.; Bolognesi, G.; Baricordi, O. R.. Nucleotide receptors: an emerging family of regulatory molecules in blood cells. Blood 2001, 97, 587-600.
4. Miras-Portugal, M. T.; Diaz-Hernandez, M.; Giraldez, L.; Hervas, C.; Gomez-Villafuerte, R.; Sen, R. P.; Gualix, J.; Pintor, J. P2X7 receptors in rat brain: presence in synaptic terminals and granule cells. Neurochem. Res. 2003, 28, 1597-1605.
5. 7 receptor subunit of the adenosine 5′ -triphosphate-gated ion channel in the developing and adult rat cochlea. Audiol. Neurootol. 2003, 8, 28-37.
6. Lee, H. Y.; Bardini, M.; Burnstock, G. P2X receptor immunoreactivity in the male genital organs of the rat. Cell Tissue Res. 2000, 300, 321-330.
7. 7 receptor coupled to ion fluxes, microvesicle formations and IL-6 release. J. Cell Sci. 1999, 112, 297-305.
8. 7 receptor. Receptors Channels 1998, 5, 347-354.
9. 7 receptor. J. Biol. Chem. 2001, 276, 11135-11142.
10. 7 receptor gene and chronic lymphocytic leukemia: a molecular study. Lancet 2002, 359 1114-1119.
11. 7 receptor gene and survival in chronic lymphocyitc leukaemia. Lancet 2002, 360, 1935-1939.
12. 7 receptor expression in evolutive and indolent forms of chronic B lymphocytic leukemia. Blood 2002, 99 706-708.
13. 7 receptor of CLL lymphocytes-a molecule with a split personality. Lancet 2002, 360, 1898-1899.
14. 7 receptor. J. Biol. Chem. 2003, 278, 17108-17113.
15. 7), Science 1996, 272, 735-738.
16. 7 receptor cell surface expression and cytolytic pore formation are regulated by a distal C-terminal region. J. Biol. Chem. 2003, 278, 8853-8860.
17. 7 contains multiple protein and lipid-interaction motifs including a potential binding site for bacterial lipopolysaccharide. J. Immunol. 2001, 167, 1871-1876.
18. 7 receptor signalling complex. EMBO J. 2001, 20:6347-6358.
19. Torres, G. E.; Egan, T. M.; Voigt, M. M. Hetero-oligomeric assembly of P2X receptor subunits. J. Biol. Chem. 1999, 274, 6653-6659.
20. 7 receptor in immune cells of the brain and the periphery. J. Biol. Chem. 2001, 276, 23262-23267.
21. 7 receptors. Am. J. Physiol. Cell Physiol. 2002, 283, C77-C84.
22. Falzoni, S.; Munerati, M.; Ferrari, D.; Spisani, S.; Moretti, S.; Di Virgilio, F. The purinergic P2Z receptor of human macrophage cells. Characterization and possible physiological role. J. Clin. Invest. 1995, 95:1207-1216.
23. 4-permeabilizes the plasma membrane of mouse macrophages to fluorescent dyes. J. Biol. Chem. 1987, 262, 8884-8888.
24. Filippini, A.; Taffs, R. E.; Agui, T.; Sitkovsky, M. V. Ecto-ATPase activity in cytolytic T lymphocytes. Protection from the cytolytic effects of extracellular ATP. J. Biol. Chem. 1990, 265, 334-340.
25. Groeschel-Stewart, U.; Bardini, M.; Robson, T.; Burnstock, G. Localisation of P2X5 and P2X7 receptors by immunohistochemistry in rat stratified squamous epithelia. Cell Tissue Res. 1999, 296 599-605.
26. Ramirez, A. N.; Kunze, D. L. P2X purinergic receptor channel expression and function in bovine aortic endothelium. Am. J. Physiol. Heart Circ. Physiol. 2002, 282, H2106-2116.
27. Perregaux, D.; Gabel, C. Interleukin-1$ maturation and release in response to ATP and nigericin. Evidence that potassium depletion mediated by these agents is a necessary and common feature of their activity. J. Biol. Chem. 1994, 269, 15195-15203.
28. Sanz, J. M.; Di Virgilio, F. Kinetics and mechanism of ATP-dependent IL-1$ release from microglial cells, J. Immunol. 2000, 164, 4893-4898.
29. 7 receptor-activated microglia. J. Neurosci. 2004 24, 1-7.
30. Ferrari, D.; Wesselborg, S.; Bauer, M. K.; Schulze-Osthoff, K. Extracellular ATP activates transcription factor NF-6B through the P2Z purinoceptor by selectively targeting NF-6B3 p65. J. Cell Biol. 1997, 139, 1635-1643.
31. 7/P2Z purinoreceptor-mediated activation of transcription factor NFAT in microglial cells. J. Biol. Chem. 1999, 274, 13205-13210.
32. 7 receptors activate protein kinase D and p42/p44 mitogen-activated protein kinase (MAPK) downstream of protein kinase C. Biochem. J. 2002, 366, 745-755.
33. 7 nucleotide receptor. J. Biol. Chem. 2000 275, 26792-16798.
34. Di Virgilio, F.; Bronte, V.; Collavo, D.; Zanovello, P. Responses of mouse lymphocytes to extracellular adenosine 5′-triphosphate (ATP). J. Immunol. 1989, 143, 1955-1960.
35. Ferrari, D.; Los, M.; Bauer, M. K.; Vandenabeele, P.; Wesselborg, S.; Schulze-Osthoff, K. P2Z purinoreceptor ligation induces activation of caspases with distinct roles in apoptotic and necrotic alterations of cell death. FEBS Lett 1999, 447, 71-75.
36. 7 ATP receptor. J. Biol. Chem. 1999, 274, 33206-33208.
37. Slater, M.; Danieletto, S.; Pooley, M.; Teh, L. C.; Gidley-Baird, A.; Barden, J. A. Differentiation between cancerous and normal hyperplastic lobules in breast lesions. Breast Cancer Res Treat. 2004, 83, 1-10.
38. 7 receptors. Histopathology 2004 44, 206-215.
39. 2Z-purinoceptor of human lymphocytes: actions of nucleotide agonists and irreversible inhibition by oxidized ATP. Br. J. Pharmacol. 1994, 112, 946-950.
40. 4- receptor of rat mast cells. Biochem. J. 1980, 188, 789-798.
41. Ralevic, V.; Burnstock, G. Receptors for purines and pyrimidines. Pharm. Rev. 1998, 50, 413-492.
42. Murgia, M.; Hanau, S.; Pizzo, P.; Rippa, M.; Di Virgilio F. Oxidised ATP. An irreversible inhibitor of the macrophage purinergic P2Z receptor. J. Biol. Chem. 1993, 268, 8199-8203.
43. Wiley, J.S.; Chen, J.R.; Snook, M.B.; Jamieson, G.P. The P2Z-purinoceptor of human lymphocytes: actions of nucleotide agonists and irreversible inhibition by oxidized ATP. Br. J. Pharmacol. 1994 112, 946-950.
44. Leff, P.; Wood, B.E.; O'Connor, S.E. Suramin is a slowly-equilibrating but competitive antagonist at P2X-receptors in the rabbit isolated ear artery. Br. J. Pharmacol. 1990, 101 645-649.
45. + uptake: inhibition of fluxes by suramin. Arch. Biochem. Biophys. 1993, 305, 54-60.
46. 7 receptor. Neuropharmacol. 1997, 36, 1285-1294.
47. 7 receptors. Mol. Pharmacol. 2000, 58, 82-88.
48. Gargett, C.E.; Wiley, J.S. The isoquinoline derivative KN-62: a potent antagonist of the P2Z receptor of human lymphocytes. Br. J. Pharmacol. 1997, 120, 1483-1490.
49. Hidaka, H.; Kobayashi, R. Pharmacology of protein kinase inhibitors. Ann. Rev. Pharmacol. Toxicol. 1992, 32, 377-397.
50. 2+/calmodulin protein kinase II. J. Biol. Chem. 1990, 8, 4315-4320.
51. 2+-calmodulin-dependent protein kinase I inhibitor on GABA release in cerebrospinal fluid of the rat. J. Pharmacol. Exp. Ther. 1990 2, 598-602.
52. 7-receptor containing the tyrosine moiety Arzneimittel-Forschung/ Drug Research , 2002, 52, 273-285.
53. Baraldi, P.G.; Romagnoli, R.; Tabrizi, M.A.; Falzoni, S.; Di Virgilio, F. Synthesis of Conformationally Constrained analogues of KN-62, a potent antagonist of the P2X7-receptor. Bioorg. Med. Chem. Lett. 2000, 10, 681-684.
54. Ravi, R.G.; Kertesy, S.B.; Dubyak, G.R.; Jacobson, K.A. Potent P2X7 receptor antagonists: tyrosyl derivatives synthesized using a sequential parallel synthetic approach. Drug. Dev. Res. 2001, 54, 75-87.
55. Chen, W.; Ravi, R.G.; Kertesy, S.B.; Dubyak, G.R.; Jacobson, K.A. Functionalized congeners of tyrosine-based P2X7 receptor antagonists: probing multiple sites for linking and dimerization. Bioconjugate Chem. 2002, 13, 1100-1111.
56. 7 Receptor. J. Med. Chem. 2003, 46, 1318-1329.
57. 7 receptor antagonists. Bioorg. Med. Chem. Lett. 2003, 13 4043-4046.
58. 7 receptor antagonists. Bioorg. Med. Chem. Lett. 2003, 13, 4047-4050.
59. Gardland, A.; Buckley, K.A.; Bowler, W.B.; Gallagher, J.A. Blockade of the pore-forming P2X7 receptor inhibits formation of multinucleated human osteoclasts in vitro. Calcif. Tissue Int. 2003, 73, 361-369.